Allergan PLC (AGN)

215.01
6.50 2.90
NYSE : Health Care
Prev Close 221.54
Open 222.08
Day Low/High 213.39 / 223.04
52 Wk Low/High 184.50 / 256.80
Volume 5.41M
Avg Volume 1.96M
Exchange NYSE
Shares Outstanding 334.31M
Market Cap 73.64B
EPS 38.20
P/E Ratio N/A
Div & Yield 2.80 (1.30%)

Latest News

Stock Observations; Reviewing Equities: Doug Kass' Views

Stock Observations; Reviewing Equities: Doug Kass' Views

Doug Kass shares his thoughts on some key stocks and reviews some equities.

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Patent lawyers are intrigued and competitors will likely challenge, but the move to transfer ownership of the patent to the Saint Regis Mohawk tribe could cause other companies to try a similar tack.

Teva's New CEO Brings This Secret Weapon

Teva's New CEO Brings This Secret Weapon

The Israel-based drugmaker on Monday tapped Kare Schultz as its new CEO. Schultz, who hails from Denmark-based Lundbeck, succeeds Dr. Yitzhak Peterburg, who has served as interim CEO since February.

Weekly Roundup

Hurricane Irma damage is less than expected, which lifts markets. In the portfolio, we add to one position while updating the ratings on two others.

FDA Approves Amgen And Allergan's MVASI™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer

FDA Approves Amgen And Allergan's MVASI™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer

Approval Based on Totality of Evidence From Global Development Program Showing MVASI™ is Highly Similar to Avastin® (bevacizumab)

Will Allergan's Deal With Tribe Hold Up?

Will Allergan's Deal With Tribe Hold Up?

Answering questions from the biotech mailbag.

Allergan Launches New Brilliant Distinctions® Patient Loyalty Program

Allergan Launches New Brilliant Distinctions® Patient Loyalty Program

Best-in-Class Program with More Than Three Million Members Updated For More Rewarding User Experience Through New Digital Platform

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)

Jim Cramer says it's a very rare moment when the absence of negatives, however fleeting or relative, creates a stampede of buying.

Allergan, USG Corp, Arena Pharmaceuticals: 'Mad Money' Lightning Round

Allergan, USG Corp, Arena Pharmaceuticals: 'Mad Money' Lightning Round

Jim Cramer is bullish on Allergan, USG Corp, and Arena Pharmaceuticals.

Irma to Bring Droves to Aisles of Home Depot; Teva Reveals Savior CEO - ICYMI

Irma to Bring Droves to Aisles of Home Depot; Teva Reveals Savior CEO - ICYMI

Here's what you need to know now for Monday, September 11.

Goldman Sachs Could Be Another Negative Tell; Takeaways: Doug Kass' Views

Goldman Sachs Could Be Another Negative Tell; Takeaways: Doug Kass' Views

Doug Kass shares his thoughts on Goldman Sachs as well as running through some of his takeaways and observations.

The Media Is the Message; Allergan Gets Jiggy: Doug Kass' Views

The Media Is the Message; Allergan Gets Jiggy: Doug Kass' Views

Doug Kass shares his thoughts on Comcast, Apple, Disney and a few other companies.

Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress

Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress

Study Between ABP 980 and Trastuzumab in Patients With HER2-Positive Early Breast Cancer Adds to the Totality of Evidence of Biosimilarity

Weekly Roundup

Markets keep an eye on the storms while the Fed has a surprise. We add a name to the portfolio.

Allergan Shares Rise on Novel Patent Pact for Restasis

Allergan Shares Rise on Novel Patent Pact for Restasis

The drugmaker unveiled an agreement that transfers patents for Restasis, Allergan's longstanding dry eye medication, to the Saint Regis Mohawk Tribe, which claims immunity from patent challenges.

2 Small Biotechs Under $5 May Be Bargains

2 Small Biotechs Under $5 May Be Bargains

T2 Biosystems and Synergy Pharmaceuticals offer promising prospects at reasonable prices.

Allergan And Saint Regis Mohawk Tribe Announce Agreements Regarding RESTASIS® Patents

Allergan And Saint Regis Mohawk Tribe Announce Agreements Regarding RESTASIS® Patents

- The Tribe Is Filing Motion to Dismiss Inter Partes Review of RESTASIS Patents Based on its Sovereign Immunity -

Follow a Moving Target: Transports

Airlines collapse due to storms, but sector hangs on.

Doubt Is OK; The Lay of the Land: Doug Kass' Views

Doubt Is OK; The Lay of the Land: Doug Kass' Views

Doug Kass shares his thoughts on doubt and tells us what the lay of the land is.

Weekly Roundup

Markets advance despite Hurricane Harvey, North Korea impacts.

Plan for August Has Worked Out

Cash-building thesis has been validated.

How A Girl from India Came to Rule JPM's North America M&A Group

How A Girl from India Came to Rule JPM's North America M&A Group

Getting M&A insight from JPM's Anu Aiyengar is like winning the lotto.

Snap, Kinder Morgan, Iconix Brands: 'Mad Money' Lightning Round

Snap, Kinder Morgan, Iconix Brands: 'Mad Money' Lightning Round

Jim Cramer is bearish on Iconix Brands, Kinder Morgan, Snap and GW Pharmaceuticals.

Stay Focused on the Green Lights: Cramer's 'Mad Money' Recap (Wed 8/30/17)

Stay Focused on the Green Lights: Cramer's 'Mad Money' Recap (Wed 8/30/17)

From political signals to the rebuilding and recovery efforts in Texas, Jim Cramer says investors should pay attention to what's supporting stocks.

ALLERGAN 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors Of Deadline In Class Action Lawsuit Against Allergan, Inc. - (AGN)

ALLERGAN 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors Of Deadline In Class Action Lawsuit Against Allergan, Inc. - (AGN)

ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until August 29, 2017 to file lead plaintiff applications in a securities class action lawsuit against Allergan, Inc.

Allergan Announces Settlement Of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patent Litigation With Famy Care

Allergan Announces Settlement Of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patent Litigation With Famy Care

-- Agreement Provides Dismissal of Litigation and Termination of Pending IPR Petitions --

TheStreet Quant Rating: C (Hold)